Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04937166 · ClinicalTrials.gov registry record · Phase 1
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
A Phase 1 study, sponsored by Kahr Medical.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT04937166: Clinical Trial Phase 1 study, sponsored by Kahr Medical.
NCT04937166 is a Phase 1 study that was terminated before completion, run by Kahr Medical. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04937166, a Phase 1 study, was terminated before completion, sponsored by Kahr Medical.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation study to explore the safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) profile of DSP107 when administered in combination with azacitidine (AZA). Part B is a dose escalation study to explore the safety, efficacy, PK and PD profile of DSP107 when administered in combination with AZA and venetoclax (VEN).
Primary Outcome
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- BIOLOGICAL DSP107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-01-13 |
| Est. Completion | 2025-10-24 |
| Phase | Phase 1 |
Why NCT04937166 stopped before completion
NCT04937166 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT04937166 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04937166 about?
NCT04937166 is a clinical study titled "A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies". This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation study to explore the safety, efficacy, pharmacokineti...
What is the current status of trial NCT04937166?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-01-13. Estimated completion is 2025-10-24.
What interventions are being tested in trial NCT04937166?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), DSP107 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04937166?
This trial is sponsored by Kahr Medical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04937166's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI